After several flops, Merck exec stands by aggressive Keytruda prostate cancer program

Prostate cancer is giving Merck & Co.’s seemingly unstoppable Keytruda a hard time. But even after three pivotal trial flops in less than a year, the New Jersey drugmaker is still hopeful that the PD-1 king can eventually crack the tumor type one way or another.